Skip to main content
OpenTrials
Completed

NCT Number: NCT00280475

A Trial of Postoperative Whole Brain Radiation Therapy vs. Salvage Stereotactic Radiosurgery Therapy for Metastasis

The aim of this study is to evaluate non-inferiority of salvage stereotactic radiosurgery (SRS) in the patients who received surgical resection for brain metastases in comparison with postoperative whole brain radiation therapy (WBRT).

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Nagoya University School of Medicine, Nagoya,Showa-ku,Tsurumai-cho,65, Aichi-ken, Japan

Loading trial locations.

About this study

A randomized phase III study is started in Japan to compare postoperative whole brain radiation therapy with salvage stereotactic radiosurgery in patient with one to four brain metastases from lung, breast, and colorectal cancer.

Total of 270 patients will be accrued for this study from 21 institutions within three years. The primary endpoint is overall survival. The secondary endpoints are proportion of performance status (PS) preservation, proportion of mini-mental status examination (MMSE) preservation, and adverse events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • one to four brain metastases with a maximum diameter of 3 cm or more for the largest lesion and additional lesions not exceeding 3 cm in diameter
  • all brain metastases localized within cerebrum or cerebellum
  • before surgical resection for brain metastasis, PS is 0-2, or 3 by cerebral nerve compression neurological deficits
  • surgical resection for the largest brain metastases has achieved
  • after surgical resection, four or fewer (0-4) residual lesions with maximum diameter under 3 cm
  • histologically proven non-small cell carcinoma, breast cancer or colorectal cancer
  • primary lesion and the other metastases (i.e. lung, liver, bone metastases except for brain) is consider to be controlled
  • an age of 20-79 years
  • no prior surgery or irradiation for brain
  • adequate organ function
  • written informed consent(If signing in consent form is difficult for the patient due to paralysis, signing by the family in place of the patient is permitted)

Exclusion criteria

  • synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ or mucosal cancer
  • pregnant or breast-feeding women
  • severe mental disease
  • allergic to gadolinium contained contrast agents

Treatment and study plan

Whole brain radiation therapy arm

Device

Whole brain radiation therapy arm

Salvage stereotactic radiosurgery arm

Device

Salvage stereotactic radiosurgery arm

Primary outcomes

  1. overall survival

    Time frame: During the study conduct

Secondary outcomes

  1. proportion of performance status (PS) preservation

    Time frame: During the study conduct

  2. proportion of mini-mental status examination (MMSE) preservation

    Time frame: During the study conduct

  3. adverse events

    Time frame: During the study conduct

Sponsors and collaborators

Lead sponsor

Haruhiko Fukuda

Other

Collaborators

  • Ministry of Health, Labour and Welfare, Japan

Registry information

Official study title

Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504)

Important dates

Study start
2006
Primary completion
2013
Study completion
2013
First posted
Jan 23, 2006
Registry last updated
Sep 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.